GLP-1 Medications for Medical Weight Loss
GLP-1 receptor agonists are a class of medications proven to assist in medical weight loss by targeting appetite regulation and gastric emptying. This page provides a comprehensive overview of the available options, their mechanisms, and what you need to know about the prescribing process.
Understanding GLP-1 Medications
GLP-1 (Glucagon-Like Peptide-1) medications mimic a natural hormone in your body that helps regulate blood sugar, slows down digestion, and signals fullness to the brain. For weight loss, these medications have shown significant clinical efficacy. The two main active ingredients utilized in modern programs are:
Semaglutide
A GLP-1 receptor agonist that acts solely on the GLP-1 pathway. It is the active ingredient in FDA-approved medications like Wegovy and Ozempic.
- • Single mechanism (GLP-1 only)
- • Extensive clinical data
- • Usually administered weekly
Tirzepatide
A dual-action medication that targets both GLP-1 and GIP receptors. It is the active ingredient in FDA-approved medications like Zepbound and Mounjaro.
- • Dual mechanism (GLP-1 + GIP)
- • Enhanced metabolic signaling
- • Usually administered weekly
FDA-Approved vs. Compounded
It is critical to distinguish between brand-name and compounded medications. FDA-approved brands (Wegovy, Zepbound, etc.) have undergone rigorous safety, efficacy, and manufacturing testing by the FDA. Compounded medications contain the same active ingredients and are legally produced during national drug shortages, but they are not FDA-approved and are not evaluated by the FDA for safety or quality.
Why Medication Alone Isn't Enough
Prescription medications are powerful tools, but they require clinical oversight and behavioral changes to yield sustainable results. Provider support is essential for:
During your consultation, a licensed healthcare provider will evaluate your complete medical profile and help you decide which, if any, medication is appropriate. A prescription is never guaranteed without this comprehensive evaluation.
Important Medical & Safety Notice
GLP-1 and GLP-1/GIP receptor agonists are prescription-only medications requiring evaluation by a licensed provider. They are not appropriate for everyone.
Patients must disclose their full medical history. These medications carry risks, including common side effects like nausea and gastrointestinal distress, and rare but serious risks like thyroid tumors or pancreatitis.
Seek urgent care for serious symptoms. This content is not a substitute for professional medical advice.
Dive Deeper into Medications
Semaglutide Detail
Comprehensive guide to semaglutide.
Tirzepatide Detail
Learn about the dual-action mechanism.
Compare Options
Which mechanism does what?
Side Effects Guide
What to expect and how to manage.
GLP-1 Safety
Contraindications and risk factors.
Programs in Sarasota
Local telehealth access details.
Medical Disclaimer: The information provided on this page is for educational purposes only and does not constitute medical advice. Prescription of any medication, including GLP-1 receptor agonists, requires a comprehensive evaluation by a licensed healthcare provider to determine medical appropriateness. Results vary by individual.
MEDICAL SOURCES & FURTHER READING
These sources address the topics identified below. They provide general education, not individualized medical advice, a clinic endorsement or a prediction of your results. Prescription treatment requires evaluation by a licensed provider; eligibility, medication and dosing depend on individual circumstances.
NIH — National Institute of Diabetes and Digestive and Kidney Diseases
Prescription Medications to Treat Overweight & ObesityWeight-management medication eligibility, appetite, lifestyle support and individualized treatment decisions.
U.S. Food and Drug Administration
Wegovy prescribing information and Medication Guide (PDF)Semaglutide indications, mechanism, contraindications, thyroid warning, pancreatitis, pregnancy and adverse reactions; this label does not apply to compounded products.
U.S. Food and Drug Administration
Zepbound prescribing information and Medication Guide (PDF)Tirzepatide indications, dual GIP/GLP-1 mechanism, contraindications and adverse reactions; this label does not apply to compounded products.
U.S. Food and Drug Administration
FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight LossLack of FDA approval for compounded drugs, dosing errors, quality concerns and limits on compounding.
RESEARCH & REFERENCES
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding, Rachel L. Batterham, Salvatore Calanna, et al.; STEP 1 Study Group · New England Journal of Medicine · 2021
Research published in the New England Journal of Medicine reported greater mean weight reduction with semaglutide plus lifestyle intervention than with placebo in the studied population. This was not a study of Sarasota Trim Clinic or compounded medication, and individual results vary.
- Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad, et al.; SURMOUNT-1 Investigators · New England Journal of Medicine · 2022
Research published in the New England Journal of Medicine reported weight reduction across the tirzepatide groups during a 72-week trial with lifestyle intervention. Results depended on the trial regimen and population, do not establish compounded-product equivalence, and are not a clinic outcome or a guarantee.